Lyka Labs Ltd

At Rs 69.99, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lyka Labs Ltd locked at its upper circuit of 5.0% on 5 Aug 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 67.03, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lyka Labs Ltd locked at its upper circuit of 4.98% on 4 Aug 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 63.84, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lyka Labs Ltd locked at its upper circuit of 5% on 3 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 July 2026, providing investors with the latest insights into the company’s performance and outlook.

At Rs 65.3, sellers were still queuing — but there were no buyers willing to take the other side. Lyka Labs Ltd locked at its lower circuit of 5% on 21 Jul 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 January 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 15 July 2026, providing investors with the latest perspective on the company’s position.

At Rs 72, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lyka Labs Ltd locked at its upper circuit of 2.8% on 10 Jul 2026, with buyers queuing and no sellers willing to part with shares.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Jan 2026, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 04 July 2026, providing investors with the latest perspective on its fundamentals, valuation, financial trend, and technical standing.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 Jan 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 11 June 2026, providing investors with the latest insights into the company’s performance and outlook.

At Rs 77.05, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lyka Labs Ltd locked at its upper circuit of 8.19% on 10 Jun 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 70.05, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lyka Labs Ltd locked at its upper circuit of 9.99% on 09 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Jan 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 29 May 2026, providing investors with the latest perspective on the company’s position.

Lyka Labs Ltd. plunged into severe operational distress in Q4 FY26, reporting a consolidated net loss of ₹7.61 crores compared to a profit of ₹1.77 crores in Q4 FY25—a staggering deterioration of 529.94%. The micro-cap pharmaceutical company, with a market capitalisation of ₹221.00 crores, saw revenues contract 16.15% year-on-year to ₹28.03 crores whilst operating margins collapsed into deeply negative territory at -23.05%, marking the worst quarterly performance in recent history.

At Rs 58.73, Lyka Labs Ltd locked at its lower circuit on 18 May 2026, falling 4.69% within a 5% price band. The session ended with unfilled supply as sellers queued at the floor price but buyers remained absent, freezing trading and highlighting the liquidity challenges faced by this micro-cap pharmaceutical stock.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Jan 2026, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 18 May 2026, providing investors with the latest insights into its performance and prospects.